News

EMA recommends drug receive orphan designation for PNH


 

Red blood cells

The European Medicines Agency (EMA) has recommended orphan drug designation for the complement C3 inhibitor APL-2 as a treatment for paroxysmal nocturnal hemoglobinuria (PNH).

APL-2 is a synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b, blocking all 3 pathways of complement activation (classical, lectin, and alternative).

This comprehensive inhibition of complement-mediated pathology may have the potential to control symptoms and modify underlying disease in patients with PNH, according to Apellis Pharmaceuticals, Inc., the company developing APL-2.

APL-2 has been evaluated in a pair of phase 1 studies of healthy volunteers. Results from these studies were presented at the 2016 ASH Annual Meeting (abstract 1251).

Now, Apellis is evaluating APL-2 in PNH patients in a pair of phase 1b trials.

In PADDOCK (NCT02588833), researchers are assessing the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple doses of APL-2 administered by daily subcutaneous injection in patients with PNH who have not received the standard of care in the past.

In PHAROAH (NCT02264639), researchers are assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of APL-2 administered by subcutaneous injection as an add-on to the standard of care in patients with PNH.

About orphan designation

Orphan designation provides regulatory and financial incentives for companies to develop and market therapies that treat life-threatening or chronically debilitating conditions affecting no more than 5 in 10,000 people in the European Union, and where no satisfactory treatment is available.

Orphan designation provides a 10-year period of marketing exclusivity if the drug receives regulatory approval. The designation also provides incentives for companies seeking protocol assistance from the EMA during the product development phase and direct access to the centralized authorization procedure.

The EMA adopts an opinion on the granting of orphan drug designation, and that opinion is submitted to the European Commission for a final decision. The European Commission typically makes a decision within 30 days.

Recommended Reading

FDA: REMS no longer necessary for epoetin, darbepoetin
MDedge Hematology and Oncology
Eltrombopag improves frequency, speed, robustness of hematologic recovery
MDedge Hematology and Oncology
FDA boxed warning leads to drop off in use of ESAs
MDedge Hematology and Oncology
In sickle cell disease, osteomyelitis is a tough call
MDedge Hematology and Oncology
PPIs triple heart failure hospitalization risk in atrial fib patients
MDedge Hematology and Oncology
Drug elicits responses in MDS patients
MDedge Hematology and Oncology
Novel inhibitor proves ‘potent’ in hematologic malignancies
MDedge Hematology and Oncology
Study shows similar outcomes with RIC and MAC in MDS
MDedge Hematology and Oncology
Role of TET2 in hematologic malignancies
MDedge Hematology and Oncology
Combo improves response rates in treatment-naïve SAA
MDedge Hematology and Oncology